Reported Saturday, UroGen Announced ATLAS Study Results At AUA 2024: UGN-102 Demonstrates Sustained Response In New And Recurrent Bladder Cancer Patients
Portfolio Pulse from Benzinga Newsdesk
UroGen Pharma Ltd. announced results from the ATLAS trial, showing that UGN-102 demonstrates sustained response rates in both new and recurrent bladder cancer patients at 12 months. The study focused on low-grade intermediate-risk non-muscle invasive bladder cancer patients treated with UGN-102, with or without subsequent TURBT.
May 06, 2024 | 7:42 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UroGen Pharma Ltd. announced promising results from the ATLAS trial for UGN-102 in treating bladder cancer, showing sustained response rates at 12 months.
The positive results from the ATLAS trial for UGN-102 in treating bladder cancer patients could significantly impact UroGen Pharma's stock price in the short term. Positive trial results often lead to increased investor confidence, potentially driving up the stock price as the market reacts to the news of a successful treatment that could lead to regulatory approval and commercialization.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100